公开(公告)号：US20190085087A1

公开(公告)日：2019-03-21

申请号：US16192008

申请日：2018-11-15

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  G01N33/574 ,  A61P35/00

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20220298576A1

公开(公告)日：2022-09-22

申请号：US17554966

申请日：2021-12-17

Applicant: Genentech, Inc.

Inventor： Luciana MOLINERO ,  Priti HEGDE

IPC: C12Q1/6886

Abstract: The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.

公开(公告)号：US20230151103A1

公开(公告)日：2023-05-18

申请号：US17886809

申请日：2022-08-12

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Luciana MOLINERO ,  Sanjeev MARIATHASAN ,  Shannon TURLEY ,  Jillian ASTARITA ,  Rafael CUBAS ,  Yagai YANG

IPC: C07K16/28 ,  C12Q1/6886 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/2866 ,  A61P35/00 ,  C07K16/2827 ,  C12Q1/6886 ,  G01N33/5743 ,  G01N33/57415 ,  G01N33/57492 ,  C07K2317/24 ,  C07K2317/32 ,  C07K2317/75 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The invention provides methods for identifying an individuals with a disease or disorder who is less likely to respond to immunotherapy alone, the method comprising determining the presence of a stromal gene signature in a sample from the individual, said signature comprising one or more of FAP, FN1, MMP2, PDGFRB, or THY, wherein an increase in the level of expression of the one or more genes in the stroma gene signature relative to a median level identifies an individual for treatment with an immunotherapy and with a suppressive stromal antagonist. In some aspects, the invention provides methods for treating an individual displaying the stromal gene signature. In other aspects, the invention provides kits for determining the presence of a stroma gene signature in a sample from an individual.

公开(公告)号：US20170260594A1

公开(公告)日：2017-09-14

申请号：US15609473

申请日：2017-05-31

Applicant: Genentech, Inc.

Inventor： Luciana MOLINERO ,  Priti HEGDE

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The invention provides methods of using expression levels of one or more immune cell gene signatures and/or combinations of immune cell gene signatures as selection criteria for selecting a patient having cancer for treatment with an immunotherapy. The invention further provides methods for selecting a patient having cancer who may benefit from a particular immunotherapy, such as an activating immunotherapy or a suppressing immunotherapy and administering to the patient the activating immunotherapy or suppressing immunotherapy to treat the cancer.